Amgen Says A Second Phase 3 Clinical Trial Is Ongoing In Japan Evaluating TEPEZZA Among Adults With Chronic TED And A Low CAS
Amgen Says A Second Phase 3 Clinical Trial Is Ongoing In Japan Evaluating TEPEZZA Among Adults With Chronic TED And A Low CAS
安進表示，日本正在進行第二階段3臨床試驗，評估TEPEZZA對慢性TED成人和低CAS的療效
Amgen Says A Second Phase 3 Clinical Trial Is Ongoing In Japan Evaluating TEPEZZA Among Adults With Chronic TED And A Low CAS
安進表示，日本正在進行第二階段3臨床試驗，評估TEPEZZA對慢性TED成人和低CAS的療效
The primary endpoint in the trial was met, as 89% of patients treated with TEPEZZA had a clinically meaningful improvement in proptosis (≥2 mm) compared with placebo (11%; p<0.0001) at week 24. The safety profile was consistent with the complete body of clinical data supporting TEPEZZA.3 A second Phase 3 clinical trial is ongoing in Japan evaluating TEPEZZA among adults with chronic TED and a low CAS (jRCT2031220730).
試驗的主要終點已達成，89%接受TEPEZZA治療的患者在24周時，眼球前突得到臨床意義重大的改善（≥2mm），明顯優於安慰劑組（11%；p
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。